Financial Advocates Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Financial Advocates Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-691	Closed	-$438K	–	737
2025 Q1	$438K	Buy	691 +26	+4%	+$17.9K	0.03%	454
2024 Q4	$474K	Buy	+665	New	+$558K	0.03%	466
2024 Q2	–	Sell	-392	Closed	-$377K	–	811
2024 Q1	$377K	Sell	392 -1	-0.3%	-$951	0.02%	523
2023 Q4	$345K	Buy	393 +80	+26%	+$65.9K	0.02%	509
2023 Q3	$258K	Buy	313 +4	+1%	+$3.14K	0.02%	570
2023 Q2	$222K	Sell	309 -90	-23%	-$69.4K	0.02%	616
2023 Q1	$328K	Buy	+399	New	+$301K	0.02%	528
2022 Q2	–	Sell	-287	Closed	-$200K	–	770
2022 Q1	$200K	Buy	+287	New	+$182K	0.01%	687
2021 Q4	–	Sell	-492	Closed	-$298K	–	806
2021 Q3	$298K	Buy	492 +47	+11%	+$29.2K	0.02%	618
2021 Q2	$248K	Buy	+445	New	+$225K	0.02%	649

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Financial Advocates Investment Management's REGN Position: Q2 2025 in Review

Financial Advocates Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 691 shares — an estimated $438K sold.

Financial Advocates Investment Management first reported a position in REGN in Q2 2021 and held it in 10 quarters. The position peaked at $474K in Q4 2024. 1,203 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Financial Advocates Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Financial Advocates Investment Management sold 691 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $438K.
Financial Advocates Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 10 quarters.
Financial Advocates Investment Management's Regeneron Pharmaceuticals position peaked at $474K in Q4 2024.
1,203 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Financial Advocates Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.